Clinical trials: Acute Migraine
Migraine, Migraine Disease
Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
Caffeine extracted from green tea to abort acute attack of Migraine
- Conditions
- Migraine, Migraine Disease, Migraine Headache, Migraine Headache, With or Without Aura
- Trial name
- NCT07022496
- Testing
- Caffeine (200 mg), triptans, NSAID (Nonsteroidal anti-inflammatory drugs)
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
Migraine
Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy
- Trial name
- NCT00632385
- Testing
- Eletriptan
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine Headache
IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine
This research will be conducted to see if the oral drug Cambia is as effective in relieving severe migraine headaches as the injectable drug ketorolac.
- Trial name
- NCT02664116
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Scripps Health
Migraine, Cannabis
Efficacy of Inhaled Cannabis for Acute Migraine Treatment
This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.
- Conditions
- Migraine, Cannabis, THC, CBD
- Trial name
- NCT04360044
- Testing
- THC ~5%, CBD ~12%, THC ~5% and CBD ~12%
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of California, San Diego
Asthma, Atrial Fibrillation
The Living With a Long-Term Condition Study
Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs).
- Conditions
- Asthma, Atrial Fibrillation, Cancer, Cerebrovascular Disorders
- Trial name
- LTC (NCT06072287)
- Testing
- Living with LTC Questionnaire
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- King's College London
Migraine
A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine
This study evaluates the efficacy of a range of intravenous doses of COL-144 in the treatment of migraine headache in order to select a dose range for further studies.
- Trial name
- NCT00384774
- Testing
- Lasmiditan
- Where
- 3 sites in Finland, Germany and 1 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Migraine Headache
Acute Stress Response in Migraine Sufferers
This study will examine the influence of stress and fasting on headache activity. Participants will receive both a control and stress session and be randomized to either fasting or not fasting for the visits.
- Trial name
- NCT03099070
- Testing
- Stress, Fasting
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Massachusetts General Hospital
Migraine
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- TEAM (NCT03465904)
- Testing
- Verum Cefaly® Abortive Program device
- Where
- 10 sites in United States
- Volunteers
- 607 people
- Sponsor
- Cefaly Technology
Migraine
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
- Trial name
- NCT06603623
- Testing
- BHV-2100
- Where
- 60 sites in United States
- Volunteers
- 647 people
- Sponsor
- Biohaven Therapeutics Ltd.
Migraine, With or Without Aura
Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults
The purpose of this study is to compare the efficacy and safety of BR005-036C versus placebo in subjects with Acute Migraines
- Trial name
- NCT07792681
- Testing
- BR005-036C
- Where
- 83 sites in China
- Volunteers
- 2,079 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.
Migraine
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
- Trial name
- PIONEER-PEDS1 (NCT04396236)
- Testing
- Lasmiditan
- Where
- 152 sites in United States, Belgium and 13 more
- Volunteers
- 847 people
- Sponsor
- Eli Lilly and Company
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE II (NCT02867709)
- Testing
- Ubrogepant
- Where
- 109 sites in United States
- Volunteers
- 1,686 people
- Sponsor
- Allergan
Migraine Headache, Cognitive Impairment
Treximet in Acute Migraine Headache: Assessing Cognitive Function
Migraine headache occurs frequently in women more than men and is associated with symptoms not only of significant pain but also of symptoms typically including of photophobia, phonophobia, nausea and vomiting.
- Trial name
- NCT00837044
- Testing
- Treximet, Migraine rescue medication of choice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Neurological Research Center
Migraine
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it.
- Trial name
- NCT07646613
- Testing
- ASY202
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Aspeya, Inc.
Migraine in Adolescence
Real-world Data Analysis of REN Treatment in Adolescence With Migraine
This is a Post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, Israel) in adolescents with migraine.
- Trial name
- NCT05443659
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 1,629 people
- Sponsor
- Theranica
Migraine
Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults
The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT07304518
- Testing
- PRT-064040 nasal spray
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Menopause, Migraine
The Functional Magnetic Resonance Imaging Study on the Processing of Acute Pain and Cognition Among Perimenopause Women
There lacks effective early screen system for the migraine-susceptible women during the peri-menopause period. The processing of acute pain and cognition as well as the underling functional magnetic resonance imaging (fMRI)…
- Trial name
- NCT02820974
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
Migraine Headache, Oxygen
Oxygen in Migraine Treatment
IIn this study, the investigators planned to investigate effectiveness of supplemental oxygen in patients (18-65 years) who were diagnosed as headache related to migraine without aura in the emergency department (ED).
- Trial name
- NCT05780671
- Testing
- oxygen
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Ankara Ataturk Sanatorium Training and Research Hospital
Migraine With or Without Aura
Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine
The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
- Trial name
- ANODYNE-1 (NCT03061734)
- Testing
- Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
The purpose of this study to show that zavegepant 10 milligrams given through the nose provides: freedom from pain, 2 hours after taking the medicine for the first migraine attack.
- Trial name
- NCT06103734
- Testing
- Zavegepant 10 mg
- Sponsor
- Pfizer